 The low cost of treatment for NTDs can be attributed to the large scale of the programs, free provision of drugs by pharmaceutical companies, delivery modes of drugs, and the un-paid volunteers who distribute the drugs.The economic burden of NTDs is undervalued and therefore the corresponding economic effect and cost-effectiveness of decreased prevalence of NTDs is underestimated.The investment return on measures to control neglected tropical diseases is estimated to be between 14–30 percent, depending on the disease and region.